Lipid  lowering: PCSK9 inhibitors – new kids on the block target their breakthrough

Markus Mohaupt

doi:10.4414/smw.2016.14345

Viewpoint

Vol. 146 No. 3132 (2016)

Lipid lowering: PCSK9 inhibitors – new kids on the block target their breakthrough

Markus Mohaupt

DOI: https://doi.org/10.4414/smw.2016.14345
Cite this as:: Swiss Med Wkly. 2016;146:w14345
Published: 31.07.2016

References

Koskinas K, Wilhem M, Windecker S. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance. Swiss Med Wkly. 2016;146:w14333. http://www.smw.ch/content/smw-2016-14333/
Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014;63(13):1278–88.
Yue P, Averna M, Lin X, Schonfeld G. The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. Hum Mutat. 2006;27(5):460–6.
Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79(3):514–23.
Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006;210(1):94–102.

How to Cite

1.

Mohaupt M. Lipid lowering: PCSK9 inhibitors – new kids on the block target their breakthrough. Swiss Med Wkly [Internet]. 2016 Jul. 31 [cited 2024 Apr. 20];146(3132):w14345. Available from: https://smw.ch/index.php/smw/article/view/2208

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

[1] Koskinas K, Wilhem M, Windecker S. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance. Swiss Med Wkly. 2016;146:w14333. http://www.smw.ch/content/smw-2016-14333/

[2] Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol. 2014;63(13):1278–88.

[3] Yue P, Averna M, Lin X, Schonfeld G. The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. Hum Mutat. 2006;27(5):460–6.

[4] Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79(3):514–23.

[5] Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006;210(1):94–102.